Boellaard Ronald
Department of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):1-4. doi: 10.1007/s00259-015-3182-7.
The use of (18)F-FDG PET/CT as a quantitative imaging biomarker requires standardization and harmonization of imaging procedures and PET/CT system performance to obtain repeatable and reproducible quantitative data. However, a PET/CT system optimized to meet international quantitative standards is not necessarily optimized for use as a diagnostic tool (i.e. for lesion detectability). Several solutions have been proposed and validated, but until recently none of them had been implemented commercially. Vendor-provided solutions allowing the use of PET/CT both as a diagnostic tool and as a quantitative imaging biomarker are therefore greatly needed and would be highly appreciated. In this invited perspective one such solution is highlighted.
将（18）F-FDG PET/CT用作定量成像生物标志物，需要对成像程序和PET/CT系统性能进行标准化和统一，以获取可重复和可再现的定量数据。然而，为满足国际定量标准而优化的PET/CT系统不一定针对用作诊断工具（即病变可检测性）进行了优化。已经提出并验证了几种解决方案，但直到最近，这些解决方案都没有在商业上得到应用。因此，迫切需要供应商提供的解决方案，使PET/CT既能用作诊断工具，又能用作定量成像生物标志物，这将非常受欢迎。在这篇特邀观点文章中，重点介绍了一种这样的解决方案。
